{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T01:55:49Z","timestamp":1769219749651,"version":"3.49.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,6,1]]},"DOI":"10.1093\/rheumatology\/keh567","type":"journal-article","created":{"date-parts":[[2005,3,2]],"date-time":"2005-03-02T03:37:52Z","timestamp":1109734672000},"page":"714-720","source":"Crossref","is-referenced-by-count":213,"title":["TNF-blocking agents and tuberculosis: new drugs illuminate an old topic"],"prefix":"10.1093","volume":"44","author":[{"given":"J.","family":"Keane","sequence":"first","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2005,3,1]]},"reference":[{"key":"key\n\t\t\t\t20171012073246_BIB1","doi-asserted-by":"crossref","unstructured":"Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med2001;344:1099\u2013100.","DOI":"10.1056\/NEJM200104053441415"},{"key":"key\n\t\t\t\t20171012073246_BIB2","doi-asserted-by":"crossref","unstructured":"Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis2004;38:1261\u20135.","DOI":"10.1086\/383317"},{"key":"key\n\t\t\t\t20171012073246_BIB3","doi-asserted-by":"crossref","unstructured":"Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum2003;48:319\u201324.","DOI":"10.1002\/art.10758"},{"key":"key\n\t\t\t\t20171012073246_BIB4","doi-asserted-by":"crossref","unstructured":"Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum2003;48:1853\u20137.","DOI":"10.1002\/art.11151"},{"key":"key\n\t\t\t\t20171012073246_BIB5","doi-asserted-by":"crossref","unstructured":"Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1-neutralizing agent. N Engl J Med2001;345:1098\u2013104.","DOI":"10.1056\/NEJMoa011110"},{"key":"key\n\t\t\t\t20171012073246_BIB6","doi-asserted-by":"crossref","unstructured":"Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis2003;3:578\u201390.","DOI":"10.1016\/S1473-3099(03)00741-2"},{"key":"key\n\t\t\t\t20171012073246_BIB7","doi-asserted-by":"crossref","unstructured":"Israel H, Hetherington H, Ord J. A study of tuberculosis among students of nursing. JAMA1941;117:461\u201373.","DOI":"10.1001\/jama.1941.02820360021007"},{"key":"key\n\t\t\t\t20171012073246_BIB8","doi-asserted-by":"crossref","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med2000;161:S221\u201347.","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"key":"key\n\t\t\t\t20171012073246_BIB9","doi-asserted-by":"crossref","unstructured":"Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med2004;350:2060\u20137.","DOI":"10.1056\/NEJMsa031667"},{"key":"key\n\t\t\t\t20171012073246_BIB10","doi-asserted-by":"crossref","unstructured":"Ormerod LP. Tuberculosis and anti-TNF-\u03b1 treatment. Thorax2004;59:921.","DOI":"10.1136\/thx.2004.029991"},{"key":"key\n\t\t\t\t20171012073246_BIB11","doi-asserted-by":"crossref","unstructured":"Salmon D. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine2002;69:170\u20132.","DOI":"10.1016\/S1297-319X(02)00387-1"},{"key":"key\n\t\t\t\t20171012073246_BIB12","unstructured":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2014California, 2002\u20132003. MMWR Morb Mortal Wkly Rep2004;53:683\u20136."},{"key":"key\n\t\t\t\t20171012073246_BIB13","doi-asserted-by":"crossref","unstructured":"Ledinghan J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNF\u03b1 blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology2005;44:157\u201363.","DOI":"10.1093\/rheumatology\/keh464"},{"key":"key\n\t\t\t\t20171012073246_BIB14","doi-asserted-by":"crossref","unstructured":"Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther2002;301:418\u201326.","DOI":"10.1124\/jpet.301.2.418"},{"key":"key\n\t\t\t\t20171012073246_BIB15","doi-asserted-by":"crossref","unstructured":"Keane J, Gershon S, Braun M. Tuberculosis and treatment with infliximab. N Engl J Med2002;346:623\u20136.","DOI":"10.1056\/NEJM200202213460815"},{"key":"key\n\t\t\t\t20171012073246_BIB16","doi-asserted-by":"crossref","unstructured":"Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis2004;39:1254\u20135.","DOI":"10.1086\/424455"},{"key":"key\n\t\t\t\t20171012073246_BIB17","unstructured":"Centocor I. Remicade (infliximab). Product label 2004."},{"key":"key\n\t\t\t\t20171012073246_BIB18","doi-asserted-by":"crossref","unstructured":"Rieder HL, Snider DE Jr, Cauthen GM. Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis1990;141:347\u201351.","DOI":"10.1164\/ajrccm\/141.2.347"},{"key":"key\n\t\t\t\t20171012073246_BIB19","doi-asserted-by":"crossref","unstructured":"Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum2004;50:372\u20139.","DOI":"10.1002\/art.20009"},{"key":"key\n\t\t\t\t20171012073246_BIB20","doi-asserted-by":"crossref","unstructured":"Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med2002;112:78.","DOI":"10.1016\/S0002-9343(01)00945-7"},{"key":"key\n\t\t\t\t20171012073246_BIB21","doi-asserted-by":"crossref","unstructured":"Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum2003;48:3013\u201322.","DOI":"10.1002\/art.11301"},{"key":"key\n\t\t\t\t20171012073246_BIB22","unstructured":"Fischkoff S. Preliminary analysis of phase i and ii safety data from the adalimumab (D2E7) clinical trials program. Proceedings of Advances in Targeted Therapies Meeting, Bahamas, April 27\u2013May 1, 2001."},{"key":"key\n\t\t\t\t20171012073246_BIB23","unstructured":"Perez J, Kupper H, Radin A, Spencer-Green G. Impact of screening for latent TB prior to initiating anti-TNF therapy. San Antonio (TX)(Abstract): American College of Rheumatology, 2005."},{"key":"key\n\t\t\t\t20171012073246_BIB24","doi-asserted-by":"crossref","unstructured":"Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis2004;39:295\u20139.","DOI":"10.1086\/421494"},{"key":"key\n\t\t\t\t20171012073246_BIB25","doi-asserted-by":"crossref","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum2003;48:2122\u20137.","DOI":"10.1002\/art.11137"},{"key":"key\n\t\t\t\t20171012073246_BIB26","doi-asserted-by":"crossref","unstructured":"Roach DR, Bean AGD, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol2002;168:4620\u20137.","DOI":"10.4049\/jimmunol.168.9.4620"},{"key":"key\n\t\t\t\t20171012073246_BIB27","doi-asserted-by":"crossref","unstructured":"Lopez Ramirez G, Rom W et al. Mycobacterium tuberculosis alters expression of adhesion molecules on monocytic cells. Infect Immun1994;62:2515\u201320.","DOI":"10.1128\/IAI.62.6.2515-2520.1994"},{"key":"key\n\t\t\t\t20171012073246_BIB28","doi-asserted-by":"crossref","unstructured":"Keane J, Shurtleff B, Kornfeld H. TNF-dependent BALB\/c murine macrophage apoptosis following Mycobacterium tuberculosis infection inhibits bacillary growth in an IFN-gamma independent manner. Tuberculosis (Edinb)2002;82:55.","DOI":"10.1054\/tube.2002.0322"},{"key":"key\n\t\t\t\t20171012073246_BIB29","doi-asserted-by":"crossref","unstructured":"Zganiacz A, Santosuosso M, Wang J et al. TNF-\u03b1 is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest2004;113:401\u201313.","DOI":"10.1172\/JCI18991"},{"key":"key\n\t\t\t\t20171012073246_BIB30","doi-asserted-by":"crossref","unstructured":"Flynn JL, Goldstein MM, Chan J et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity1995;2:561\u201372.","DOI":"10.1016\/1074-7613(95)90001-2"},{"key":"key\n\t\t\t\t20171012073246_BIB31","doi-asserted-by":"crossref","unstructured":"Bean AG, Roach DR, Briscoe H et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol1999;162:3504\u201311.","DOI":"10.4049\/jimmunol.162.6.3504"},{"key":"key\n\t\t\t\t20171012073246_BIB32","doi-asserted-by":"crossref","unstructured":"Mohan VP, Scanga CA, Yu K et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun2001;69:1847\u201355.","DOI":"10.1128\/IAI.69.3.1847-1855.2001"},{"key":"key\n\t\t\t\t20171012073246_BIB33","doi-asserted-by":"crossref","unstructured":"Algood HM, Lin PL, Yankura D, Jones A, Chan J, Flynn JL. TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. J Immunol2004;172:6846\u201357.","DOI":"10.4049\/jimmunol.172.11.6846"},{"key":"key\n\t\t\t\t20171012073246_BIB34","doi-asserted-by":"crossref","unstructured":"Turner J, Frank AA, Brooks JV, Marietta PM, Orme IM. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology2001;102:248\u201353.","DOI":"10.1046\/j.1365-2567.2001.01161.x"},{"key":"key\n\t\t\t\t20171012073246_BIB35","doi-asserted-by":"crossref","unstructured":"Olleros ML, Guler R, Corazza N et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis Bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-\u03b1. J Immunol2002;168:3394\u20133401.","DOI":"10.4049\/jimmunol.168.7.3394"},{"key":"key\n\t\t\t\t20171012073246_BIB36","doi-asserted-by":"crossref","unstructured":"Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology2001;121:1145\u201357.","DOI":"10.1053\/gast.2001.28702"},{"key":"key\n\t\t\t\t20171012073246_BIB37","doi-asserted-by":"crossref","unstructured":"Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology2003;124:1774\u201385.","DOI":"10.1016\/S0016-5085(03)00382-2"},{"key":"key\n\t\t\t\t20171012073246_BIB38","doi-asserted-by":"crossref","unstructured":"Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum2003;48:780\u201390.","DOI":"10.1002\/art.10847"},{"key":"key\n\t\t\t\t20171012073246_BIB39","unstructured":"Popa C, Netea M, Barrerra P, Kulberg B, Van der Meer J. Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving anti-TNF agents. Eur Cytokine Netw2003;14:61."},{"key":"key\n\t\t\t\t20171012073246_BIB40","doi-asserted-by":"crossref","unstructured":"Wood KL, Hage CA, Knox KS et al. Histoplasmosis after treatment with anti-tumor necrosis factor-\u03b1 therapy. Am J Respir Crit Care Med2003;167:1279\u201382.","DOI":"10.1164\/rccm.200206-563OC"},{"key":"key\n\t\t\t\t20171012073246_BIB41","doi-asserted-by":"crossref","unstructured":"Bergstrom L, Yocum DE, Ampel NM et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum2004;50:1959\u201366.","DOI":"10.1002\/art.20454"},{"key":"key\n\t\t\t\t20171012073246_BIB42","doi-asserted-by":"crossref","unstructured":"Obrador A, Lopez San Roman A, Munoz P, Fortun J, Gassull MA. [Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis]. Gastroenterol Hepatol2003;26:29\u201333.","DOI":"10.1016\/S0210-5705(03)70338-0"},{"key":"key\n\t\t\t\t20171012073246_BIB43","unstructured":"Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ2003;168:1153\u20136."},{"key":"key\n\t\t\t\t20171012073246_BIB44","doi-asserted-by":"crossref","unstructured":"Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis2003;3:148\u201355.","DOI":"10.1016\/S1473-3099(03)00545-0"},{"key":"key\n\t\t\t\t20171012073246_BIB45","doi-asserted-by":"crossref","unstructured":"Taylor JC, Orkin R, Lanham J. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatology2003;42:901\u20132.","DOI":"10.1093\/rheumatology\/keg158"},{"key":"key\n\t\t\t\t20171012073246_BIB46","doi-asserted-by":"crossref","unstructured":"Jasmer RM, Nahid P, Hopewell PC. Treatment of latent tuberculosis infection. N Engl J Med2003;348:1292\u20133.","DOI":"10.1056\/NEJM200303273481318"},{"key":"key\n\t\t\t\t20171012073246_BIB47","doi-asserted-by":"crossref","unstructured":"Hamilton CD. Tuberculosis in the cytokine era: what rheumatologists need to know. Arthritis Rheum2003;48:2085\u201391.","DOI":"10.1002\/art.11134"},{"key":"key\n\t\t\t\t20171012073246_BIB48","doi-asserted-by":"crossref","unstructured":"Mazurek GH, LoBue PA, Daley CL et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA2001;286:1740\u20137.","DOI":"10.1001\/jama.286.14.1740"},{"key":"key\n\t\t\t\t20171012073246_BIB49","doi-asserted-by":"crossref","unstructured":"Ewer K, Deeks J, Alvarez L et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet2003;361:1168\u201373.","DOI":"10.1016\/S0140-6736(03)12950-9"},{"key":"key\n\t\t\t\t20171012073246_BIB50","doi-asserted-by":"crossref","unstructured":"Orenstein R, Kolls JK, Zhang Z, Mannon PJ, Fuss IJ, Strober W. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med2005;352:627\u20138.","DOI":"10.1056\/NEJM200502103520619"},{"key":"key\n\t\t\t\t20171012073246_BIB51","unstructured":"Parra Ruiz J, Ortego Centeno N, Raya Alvarez E. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol2003;30:1657\u20138."},{"key":"key\n\t\t\t\t20171012073246_BIB52","unstructured":"Kim HA, Yoo CD, Baek HJ et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol1998;16:9\u201313."},{"key":"key\n\t\t\t\t20171012073246_BIB53","doi-asserted-by":"crossref","unstructured":"van Rie A, Warren R, Richardson M et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med1999;341:1174\u20139.","DOI":"10.1056\/NEJM199910143411602"},{"key":"key\n\t\t\t\t20171012073246_BIB54","doi-asserted-by":"crossref","unstructured":"Priest DH, Vossel LF Jr, Sherfy EA, Hoy DP, Haley CA. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clin Infect Dis2004;39:1764\u201371.","DOI":"10.1086\/425610"},{"key":"key\n\t\t\t\t20171012073246_BIB55","doi-asserted-by":"crossref","unstructured":"Tramontana JM, Utaipat U, Molloy A et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med1995;1:384\u201397.","DOI":"10.1007\/BF03401576"},{"key":"key\n\t\t\t\t20171012073246_BIB56","doi-asserted-by":"crossref","unstructured":"Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. Aids2004;18:257\u201364.","DOI":"10.1097\/00002030-200401230-00015"},{"key":"key\n\t\t\t\t20171012073246_BIB57","doi-asserted-by":"crossref","unstructured":"Nathan C, Sporn M. Cytokines in context. J Cell Biol1991;113:981\u20136.","DOI":"10.1083\/jcb.113.5.981"},{"key":"key\n\t\t\t\t20171012073246_BIB58","doi-asserted-by":"crossref","unstructured":"Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med1999;25:556\u201366.","DOI":"10.1007\/s001340050903"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/44\/6\/714\/9446851\/keh567.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T14:43:16Z","timestamp":1683038596000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/rheumatology\/article\/44\/6\/714\/2899250\/TNFblocking-agents-and-tuberculosis-new-drugs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,1]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,3,1]]},"published-print":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keh567","relation":{},"ISSN":["1462-0332","1462-0324"],"issn-type":[{"value":"1462-0332","type":"electronic"},{"value":"1462-0324","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,6]]},"published":{"date-parts":[[2005,3,1]]}}}